- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
JHL Biotech Doses First Patients in Denosumab Trial
Taiwan-based JHL Biotech said it has initiated a phase 1 clinical trial of its denosumab biosimilar candidate for bone loss.
Hsinchu, Taiwan—based JHL Biotech said it has initiated a phase 1 clinical trial of its denosumab biosimilar candidate JHL 1266, having randomized and treated the first group of patients.
JHL 1266 is a monoclonal antibody targeting RANKL, a gene that regulates cell death. Denosumab inhibits the development of osteoclasts, which break down bone tissue and release the minerals into the blood stream. The drug thereby prevents breakdown of bones in the human body.
Denosumab is used for the treatment of osteoporosis and hypercalcemia, or above-normal calcium levels. In the United States it is indicated for osteoporosis and improving bone mass in individuals at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.
The company said the 3-arm study is being conducted in Australia and will compare the pharmacokinetic similarity of JHL 1266 with that of the reference product, Prolia, in healthy patients. The company described the study as pivotal for regulatory approval.
“Denosumab is an important biologic for the treatment of post-menopausal osteoporosis and other common bone related diseases. Because it’s unfortunately very expensive for patients and healthcare payers, JHL1266 would provide an affordable treatment for these patients,” said James Huang, CEO of JHL Biotech, in a statement.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
